Santhera Obtains European Patent For Use of Omigapil for the Treatment of CMD

Santhera announced today that the European Patent Office granted patent protection for the use of omigapil for the treatment of Congenital Muscular Dystrophy through 2026.

Click here

This entry was posted in Research News. Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Congenital Muscular Dystrophy

    A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...

  • Register Now!